CA2219502A1 - Methods and formulations for modulating the human sexual response - Google Patents
Methods and formulations for modulating the human sexual responseInfo
- Publication number
- CA2219502A1 CA2219502A1 CA002219502A CA2219502A CA2219502A1 CA 2219502 A1 CA2219502 A1 CA 2219502A1 CA 002219502 A CA002219502 A CA 002219502A CA 2219502 A CA2219502 A CA 2219502A CA 2219502 A1 CA2219502 A1 CA 2219502A1
- Authority
- CA
- Canada
- Prior art keywords
- modulating
- sexual response
- methods
- formulations
- human sexual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Abstract
The invention is directed to improved methods for modulating the human sexual response by administering an oral administered formulation of a vasodilator agent to the blood circulation thereby modulating the sexual response on demand.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/431,145 US5731339A (en) | 1995-04-28 | 1995-04-28 | Methods and formulations for modulating the human sexual response |
US08/431,145 | 1995-04-28 | ||
PCT/US1996/005816 WO1996033705A1 (en) | 1995-04-28 | 1996-04-26 | Methods and formulations for modulating the human sexual response |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2219502A1 true CA2219502A1 (en) | 1996-10-31 |
CA2219502C CA2219502C (en) | 2002-11-19 |
Family
ID=23710676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002219502A Expired - Lifetime CA2219502C (en) | 1995-04-28 | 1996-04-26 | Methods and formulations for modulating the human sexual response |
Country Status (35)
Country | Link |
---|---|
US (6) | US5731339A (en) |
EP (2) | EP0767660B1 (en) |
JP (2) | JP3469901B2 (en) |
KR (1) | KR100363056B1 (en) |
CN (1) | CN101816638A (en) |
AR (1) | AR001739A1 (en) |
AT (1) | ATE185695T1 (en) |
AU (1) | AU710111B2 (en) |
BG (1) | BG63071B1 (en) |
BR (1) | BR9604983A (en) |
CA (1) | CA2219502C (en) |
CZ (1) | CZ294350B6 (en) |
DE (1) | DE69604762T2 (en) |
DK (1) | DK0767660T3 (en) |
EE (1) | EE03472B1 (en) |
ES (1) | ES2140847T3 (en) |
GR (1) | GR3032182T3 (en) |
HU (1) | HU222044B1 (en) |
IL (1) | IL117871A (en) |
IS (1) | IS4598A (en) |
LT (1) | LT4404B (en) |
LV (1) | LV12038B (en) |
MD (1) | MD1663C2 (en) |
NO (1) | NO314746B1 (en) |
NZ (1) | NZ307020A (en) |
PL (1) | PL185528B1 (en) |
PT (1) | PT767660E (en) |
RO (1) | RO116866B1 (en) |
RU (2) | RU2177786C2 (en) |
SI (1) | SI9620058A (en) |
SK (1) | SK283847B6 (en) |
TR (2) | TR199901973T2 (en) |
UA (1) | UA70277C2 (en) |
WO (1) | WO1996033705A1 (en) |
ZA (1) | ZA963380B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD1663C2 (en) * | 1995-04-28 | 2001-11-30 | Zonagen, Inc. | Composition and methods for human sexual activity modulation and impotency treatment |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6036977A (en) * | 1995-09-29 | 2000-03-14 | L.A.M. Pharmaceutical Corp. | Drug preparations for treating sexual dysfunction |
US6251436B1 (en) | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
US5897880A (en) | 1995-09-29 | 1999-04-27 | Lam Pharmaceuticals, Llc. | Topical drug preparations |
US6387407B1 (en) | 1995-09-29 | 2002-05-14 | L.A.M. Pharmaceutical Corporation | Topical drug preparations |
US6258032B1 (en) * | 1997-01-29 | 2001-07-10 | William M. Hammesfahr | Method of diagnosis and treatment and related compositions and apparatus |
US6294517B1 (en) | 1996-02-02 | 2001-09-25 | Nitromed, Inc. | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
US20020143007A1 (en) * | 1996-02-02 | 2002-10-03 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
US20050065161A1 (en) * | 1996-02-02 | 2005-03-24 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
US6469065B1 (en) | 1996-02-02 | 2002-10-22 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use |
US6323211B1 (en) * | 1996-02-02 | 2001-11-27 | Nitromed, Inc. | Compositions and methods for treating sexual dysfunctions |
USRE37234E1 (en) | 1996-11-01 | 2001-06-19 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US5958926A (en) * | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
GR1002847B (en) | 1997-05-06 | 1998-01-27 | Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic treatiment of problems related to the erection | |
KR20010012721A (en) * | 1997-05-19 | 2001-02-26 | 조나젠 인코포레이티드 | Combination therapy for modulating the human sexual response |
US20030004170A1 (en) * | 1997-05-19 | 2003-01-02 | Zonagen, Inc. | Combination therapy for modulating the human sexual response |
DE69833254T2 (en) * | 1997-06-23 | 2006-11-02 | Cellegy Pharmaceuticals, Inc., Brisbane | MICRODOSIS THERAPY OF VASCULAR EXPOSURE BY NO-DONORS |
KR20010021625A (en) | 1997-07-09 | 2001-03-15 | 추후보정 | Improved Methods and Compositions for Treating Male Erectile Dysfunction |
US6399618B1 (en) | 1997-07-09 | 2002-06-04 | Cardiome Pharma Corp | Compositions and methods for modulating sexual activity |
US6103765A (en) * | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
US5947901A (en) | 1997-09-09 | 1999-09-07 | Redano; Richard T. | Method for hemodynamic stimulation and monitoring |
US6593369B2 (en) | 1997-10-20 | 2003-07-15 | Vivus, Inc. | Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
US20050070516A1 (en) * | 1997-10-28 | 2005-03-31 | Vivus Inc. | As-needed administration of an androgenic agent to enhance female desire and responsiveness |
US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
JP2001520999A (en) | 1997-10-28 | 2001-11-06 | アシビ, エルエルシー | Treatment of sexual dysfunction in women |
US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
EP1054626A1 (en) | 1998-01-13 | 2000-11-29 | Urometrics, Inc. | Devices and methods for monitoring female arousal |
FR2774593B1 (en) * | 1998-02-12 | 2000-05-05 | Philippe Gorny | OBTAINING A MEDICINE TO COMBAT FEMALE SEXUAL DYSFUNCTIONS |
AU4068599A (en) * | 1998-05-20 | 1999-12-06 | Schering Corporation | Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction |
US6011043A (en) * | 1998-06-19 | 2000-01-04 | Schering Corporation | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction |
US20040170675A1 (en) * | 1998-08-03 | 2004-09-02 | Easterling W. Jerry | Noninvasive method for treating cellulite through transdermal delivery of calcium channel blocker agents and medicament for use in such method |
US6627663B2 (en) | 1998-08-03 | 2003-09-30 | W. Jerry Easterling | Noninvasive method for treating hemangiomas through transdermal delivery of calcium channel blocker agents and medicament for use in such method |
US6525100B1 (en) | 1998-08-03 | 2003-02-25 | W. Jerry Easterling | Composition and method for treating peyronie's disease and related fibrotic tissue disorders |
US6031005A (en) | 1998-08-03 | 2000-02-29 | Easterling; W. Jerry | Composition and method for treating Peyronie's disease and related connective tissue disorders |
GR1003199B (en) * | 1998-08-14 | 1999-09-01 | Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic threatment of problemes related to the female sexual malfunction | |
AU5403499A (en) * | 1998-08-26 | 2000-03-21 | Queen's University At Kingston | Methods for remodeling neuronal and cardiovascular pathways |
US6482426B1 (en) * | 1998-09-17 | 2002-11-19 | Zonagen, Inc. | Compositions for the treatment of male erectile dysfunction |
US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
US6706682B2 (en) * | 1999-01-21 | 2004-03-16 | The Trustees Of Columbia University In The City Of New York | Uses of vascular endothelial growth factor in the treatment of erectile dysfunction |
EP1161255A4 (en) * | 1999-03-08 | 2002-07-17 | Merck & Co Inc | Methods and compositions for treating erectile dysfunction |
AU4203600A (en) * | 1999-04-06 | 2000-10-23 | Zonagen, Inc. | Methods for modulating the human sexual response |
EP1173167A4 (en) | 1999-04-30 | 2004-07-14 | Lilly Icos Llc | Treatment of female arousal disorder |
IT1312310B1 (en) | 1999-05-07 | 2002-04-15 | Recordati Ind Chimica E Farma | USE OF SELECTIVE 1B ADRENERGIC RECEPTOR ANTAGONISTS TO IMPROVE SEXUAL DYSFUNCTION |
US20010003120A1 (en) * | 1999-05-14 | 2001-06-07 | M. D. Robert Hines | Method for treating erectile dysfunction |
US6916845B2 (en) * | 1999-06-17 | 2005-07-12 | Zhongcheng Xin | Method for prevention and treatment of male and female sexual dysfunction |
US6730065B1 (en) * | 2000-09-15 | 2004-05-04 | Ocularis Pharma, Inc. | Night vision composition |
US6399591B1 (en) * | 2000-01-19 | 2002-06-04 | Yung-Shin Pharmaceutical Ind. Co., Ltd. | Chargeable pharmaceutical tablets |
US6730691B1 (en) | 2000-02-10 | 2004-05-04 | Miles A. Galin | Uses of alpha adrenergic blocking agents |
CA2408417C (en) * | 2000-05-12 | 2009-09-15 | Novalar Pharmaceuticals, Inc. | Local anesthetic methods and kits |
DE60130007T2 (en) * | 2000-06-27 | 2008-04-30 | Qualilife Pharmaceuticals Inc. | COMPOSITIONS AND METHODS FOR TREATING THE FEMALE SEXUAL REACTION |
BRPI0003386B8 (en) * | 2000-08-08 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | homo- or heterodimeric prodrugs useful in treating diseases or disorders mediated by phosphodiesterases; pharmaceutical compositions containing the prodrug or its pharmaceutical acceptable salts; process of obtaining these prodrugs |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
KR20020020536A (en) * | 2000-09-09 | 2002-03-15 | 장우영 | Injection for impotency |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
US20060211753A1 (en) * | 2000-11-03 | 2006-09-21 | Ocularis Pharma, Inc. | Method and composition which reduces stimulation of muscles which dilate the eye |
US20020107230A1 (en) * | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
WO2002069906A2 (en) | 2001-03-06 | 2002-09-12 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
US20020172712A1 (en) * | 2001-03-19 | 2002-11-21 | Alan Drizen | Antiemetic, anti-motion sustained release drug delivery system |
US20030138494A1 (en) * | 2001-05-15 | 2003-07-24 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
JP2005501072A (en) | 2001-08-10 | 2005-01-13 | モレキュラー・デザイン・インターナショナル・インコーポレイテッド | New alpha adrenergic drugs |
US6969719B2 (en) * | 2001-08-28 | 2005-11-29 | Schering Corporation | Polycyclic guanine phosphodiesterase V inhibitors |
GB0130704D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | New use |
US8133903B2 (en) * | 2003-10-21 | 2012-03-13 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases |
WO2004037183A2 (en) * | 2002-10-22 | 2004-05-06 | Harbor-Ucla Research And Education Institute | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
CN100336506C (en) * | 2004-04-23 | 2007-09-12 | 北京科信必成医药科技发展有限公司 | Orally disintegrating tablet of phentolamine mesylate and its preparation method |
PT1750766E (en) | 2004-05-11 | 2013-09-30 | Emotional Brain Bv | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
CA2568640C (en) * | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
US20060167022A1 (en) * | 2004-09-08 | 2006-07-27 | Woodward John R | Method of female sexual enhancement |
US20060252734A1 (en) * | 2004-09-08 | 2006-11-09 | Woodward John R | Methods of female sexual enhancement |
US20060052402A1 (en) * | 2004-09-08 | 2006-03-09 | Woodward John R | Method of female sexual enhancement |
US20080119445A1 (en) * | 2004-09-08 | 2008-05-22 | Woodward John R | Methods of female sexual enhancement |
US20060276442A1 (en) * | 2004-09-08 | 2006-12-07 | Woodward John R | Methods of female sexual enhancement |
DE502005008880D1 (en) * | 2004-10-18 | 2010-03-04 | Polymun Scient Immunbio Forsch | LIPOSOMAL COMPOSITION CONTAINING AN ACTIVE SUBSTANCE FOR RELAXING SMOOTH MUSCULATURE, THE PREPARATION OF THIS COMPOSITION, AND THEIR THERAPEUTIC USE |
CA2601773A1 (en) * | 2005-02-03 | 2006-08-10 | Duramed Pharmaceuticals, Inc. | Compositions of unconjugated estrogens and methods for their use |
US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
NO346660B1 (en) | 2005-10-12 | 2022-11-21 | Unimed Pharmaceuticals Llc | Improved testosterone gel and method of use |
EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
WO2008151204A1 (en) | 2007-06-04 | 2008-12-11 | Sequent Medical Inc. | Methods and devices for treatment of vascular defects |
SG10201704221XA (en) * | 2012-12-05 | 2017-06-29 | Ge Nutrients Inc | Use of fenugreek extract to enhance female libido |
EP2950800B1 (en) | 2013-02-01 | 2020-09-09 | Ocuphire Pharma, Inc. | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance |
JP6335927B2 (en) | 2013-02-01 | 2018-05-30 | オキュラリス・ファーマ・リミテッド・ライアビリティ・カンパニーOcularis Pharma, Llc | Aqueous ophthalmic solutions of phentolamine and their medical uses |
CN104013588A (en) * | 2014-04-14 | 2014-09-03 | 杨荣辰 | Phentolamine mesilate dispersible tablet and preparation method thereof |
CN107427538A (en) * | 2015-04-17 | 2017-12-01 | 株式会社山田养蜂场本社 | Nourishing tonic containing honeybee |
WO2017100324A1 (en) * | 2015-12-10 | 2017-06-15 | Repros Therapeutics Inc. | Combination therapy for treating female hypoactive sexual desire disorders |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
KR20210096096A (en) | 2018-10-26 | 2021-08-04 | 오큐파이어 파마, 인크. | Methods and compositions for the treatment of presbyopia, mydriasis, and other ocular disorders |
CN115368310A (en) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | Method for synthesizing phentolamine mesylate |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2503059A (en) * | 1950-04-04 | Nxchj | ||
US3937834A (en) * | 1970-10-02 | 1976-02-10 | Ciba-Geigy Corporation | Pharmaceutical preparations |
US3943246A (en) * | 1972-07-10 | 1976-03-09 | Sandoz Ltd. | Organic compounds |
US4139617A (en) * | 1974-05-13 | 1979-02-13 | Richardson-Merrell Inc. | 19-Oxygenated-androst-5-enes for the enhancement of libido |
GB1500300A (en) * | 1975-01-06 | 1978-02-08 | Ciba Geigy Ag | Pharmaceutical preparation for the treatment of circulatory disorders |
NZ179623A (en) * | 1975-01-06 | 1978-03-06 | Ciba Geigy | Pharmaceutical preparation containing a beta-receptor blocking compound, a compound regulating thrombocyte function and optionally an alpha-receptor blocking compund |
US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
DE2965278D1 (en) * | 1978-07-21 | 1983-06-01 | Ciba Geigy Ag | Pharmaceutical mixtures containing an amantadine compound |
US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
US4530920A (en) * | 1983-11-07 | 1985-07-23 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist |
EP0152379A3 (en) * | 1984-02-15 | 1986-10-29 | Ciba-Geigy Ag | Process for preparing pharmaceutical compositions containing unilamellar liposomes |
US4885173A (en) * | 1985-05-01 | 1989-12-05 | University Of Utah | Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities |
US4863911A (en) * | 1986-08-04 | 1989-09-05 | University Of Florida | Method for treating male sexual dysfunction |
US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
US5256652A (en) * | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
SE463851B (en) * | 1988-09-02 | 1991-02-04 | Amsu Ltd | COMPOSITION FOR TREATMENT OF ERECT DYSFUNCTION THROUGH URETRA |
US5059603A (en) * | 1989-06-12 | 1991-10-22 | Centuries Laboratories, Inc. | Method and composition for treating impotence |
WO1990015583A1 (en) * | 1989-06-16 | 1990-12-27 | Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny Institut Meditsinskoi Tekhniki | Device for treating sexual weakness in men |
FR2649613B1 (en) * | 1989-07-11 | 1991-09-27 | Virag Ronald | VASO-ACTIVE MEDICINE |
US5079018A (en) * | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
US5236904A (en) * | 1989-09-18 | 1993-08-17 | Senetek, Plc | Erection-inducing methods and compositions |
US5270323A (en) * | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
US5399581A (en) * | 1990-12-26 | 1995-03-21 | Laragh; John H. | Method and compositions for treatment of sexual impotence |
US5298261A (en) * | 1992-04-20 | 1994-03-29 | Oregon Freeze Dry, Inc. | Rapidly distintegrating tablet |
US5565466A (en) * | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
US5731339A (en) * | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
-
1995
- 1995-04-28 US US08/431,145 patent/US5731339A/en not_active Expired - Lifetime
-
1996
- 1996-04-11 IL IL11787196A patent/IL117871A/en not_active IP Right Cessation
- 1996-04-26 UA UA97105248A patent/UA70277C2/en unknown
- 1996-04-26 RU RU97119646/14A patent/RU2177786C2/en active
- 1996-04-26 TR TR1999/01973T patent/TR199901973T2/en unknown
- 1996-04-26 MD MD98-0007A patent/MD1663C2/en unknown
- 1996-04-26 SI SI9620058A patent/SI9620058A/en unknown
- 1996-04-26 DE DE69604762T patent/DE69604762T2/en not_active Expired - Lifetime
- 1996-04-26 HU HU9802825A patent/HU222044B1/en active IP Right Grant
- 1996-04-26 AU AU55768/96A patent/AU710111B2/en not_active Expired
- 1996-04-26 RU RU2000100756/15A patent/RU2239424C2/en active
- 1996-04-26 AR AR33632696A patent/AR001739A1/en not_active Application Discontinuation
- 1996-04-26 WO PCT/US1996/005816 patent/WO1996033705A1/en active IP Right Grant
- 1996-04-26 NZ NZ307020A patent/NZ307020A/xx not_active IP Right Cessation
- 1996-04-26 PL PL96323087A patent/PL185528B1/en unknown
- 1996-04-26 KR KR1019970707656A patent/KR100363056B1/en not_active IP Right Cessation
- 1996-04-26 AT AT96913174T patent/ATE185695T1/en active
- 1996-04-26 EP EP96913174A patent/EP0767660B1/en not_active Expired - Lifetime
- 1996-04-26 JP JP53273896A patent/JP3469901B2/en not_active Expired - Lifetime
- 1996-04-26 EP EP99114470A patent/EP0962225A3/en not_active Withdrawn
- 1996-04-26 CA CA002219502A patent/CA2219502C/en not_active Expired - Lifetime
- 1996-04-26 BR BR9604983A patent/BR9604983A/en not_active Application Discontinuation
- 1996-04-26 ES ES96913174T patent/ES2140847T3/en not_active Expired - Lifetime
- 1996-04-26 CN CN200910151335A patent/CN101816638A/en active Pending
- 1996-04-26 CZ CZ19973393A patent/CZ294350B6/en not_active IP Right Cessation
- 1996-04-26 TR TR97/01260T patent/TR199701260T1/en unknown
- 1996-04-26 RO RO97-01998A patent/RO116866B1/en unknown
- 1996-04-26 EE EE9700276A patent/EE03472B1/en not_active IP Right Cessation
- 1996-04-26 SK SK1458-97A patent/SK283847B6/en unknown
- 1996-04-26 DK DK96913174T patent/DK0767660T3/en active
- 1996-04-26 PT PT96913174T patent/PT767660E/en unknown
- 1996-04-29 ZA ZA963380A patent/ZA963380B/en unknown
-
1997
- 1997-10-24 IS IS4598A patent/IS4598A/en unknown
- 1997-10-27 NO NO19974965A patent/NO314746B1/en not_active IP Right Cessation
- 1997-10-27 LV LVP-97-209A patent/LV12038B/en unknown
- 1997-10-28 LT LT97-168A patent/LT4404B/en not_active IP Right Cessation
- 1997-10-29 US US08/959,672 patent/US5981563A/en not_active Expired - Lifetime
- 1997-10-31 BG BG102010A patent/BG63071B1/en unknown
-
1998
- 1998-03-10 US US09/037,898 patent/US6100286A/en not_active Expired - Lifetime
-
1999
- 1999-07-28 US US09/362,518 patent/US6166061A/en not_active Expired - Lifetime
- 1999-07-28 US US09/362,825 patent/US6051594A/en not_active Expired - Lifetime
- 1999-07-28 US US09/362,486 patent/US6124337A/en not_active Expired - Lifetime
- 1999-12-17 GR GR990403268T patent/GR3032182T3/en unknown
-
2001
- 2001-07-16 JP JP2001215110A patent/JP4531301B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD1663C2 (en) * | 1995-04-28 | 2001-11-30 | Zonagen, Inc. | Composition and methods for human sexual activity modulation and impotency treatment |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2219502A1 (en) | Methods and formulations for modulating the human sexual response | |
CA2169071A1 (en) | Methods for modulating the human sexual response | |
CA2231803A1 (en) | Lipid extract having anti-inflammatory activity | |
HUP0000558A3 (en) | Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases | |
TR199600498A2 (en) | Oral formulations of S (+) - ibuprofen. | |
CA2041579A1 (en) | Dosage form | |
AU3284984A (en) | Pharmaceutical compositions for the transdermal application of active ingredients | |
CA2215329A1 (en) | Colorectal chemoprotective composition and method for preventing colorectal cancer | |
CA2092905A1 (en) | Treatment of autoimmune diseases by oral administration of autoantigens | |
MY116509A (en) | Emulsion suitable for administering a poorly water- soluble photosensitizing compound and use thereof | |
AU5355094A (en) | Therapeutic and diagnostic imaging compositions and methods | |
CA2299366A1 (en) | Use of xanthophylls for improvement of duration of muscle function or treatment of muscle disorders or diseases | |
EP1093812A3 (en) | Amoxycillin and clavulanate containing pharmaceutical formulation | |
TR199600499A2 (en) | S (+) - Oral formulations of Etodolak. | |
CA2294921A1 (en) | Levobupivacaine and its use | |
HUP0003840A2 (en) | Controlled released medical formulation | |
AU4759390A (en) | Method of medical treatment of alzheimer's disease | |
DK0629400T3 (en) | Idebenone-containing preparations for the treatment of Alzheimer's disease | |
EP0744176A3 (en) | Methods for inhibiting bone loss | |
AU1847695A (en) | Pharmaceutical formulations of cntf | |
WO1993017691A3 (en) | Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease | |
CA2313618A1 (en) | Transmucosal formulations of levosimendan | |
CA2255064A1 (en) | Potassium, sodium and tris oxaprozin salt pharmaceutical formulations | |
HUP9902415A2 (en) | Solid instant-release forms of administration and process for producing the same | |
NZ303993A (en) | Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20160426 |